Peter Hersh, MD
Ophthalmology · Teaneck, NJNPI 1366564346
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $65,250 of the $67,880 with a category attached, or 96.1%. Katena Products, Inc. (dba Corza Medical) accounts for 88.4% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2022 at $32,357 and has fallen 99.7% since, to $85 in 2025. Among ophthalmology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 31 payments — averaging $2189.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Katena Products, Inc. (dba Corza Medical)$60K
- Glaukos Corporation$7K
- Bausch & Lomb Americas Inc.$152
- Kala Pharmaceuticals, Inc.$57
- Tarsus Pharmaceuticals, Inc.$55
- Oyster Point Pharma, Inc.$48
- plus $129 from 7 others
Across 42 payments — averaging $4369.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$184K
What the payments were for
- Consulting fees$65,25096%
- Speaking & faculty fees$2,1573%
- Food & beverage$4731%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iStent inject W$750
- STELLARIS$125
How this compares
$67,880 in reported general payments places this provider in the 95th percentile of 583 ophthalmology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 12 | $5,433 |
| ValacyclovirValacyclovir Hcl | 18 | $1,994 |
| Prednisolone Acetate | 26 | $899 |
| Doxycycline Monohydrate | 15 | $378 |
| Bacitracin-PolymyxinBacitracin/Polymyxin B Sulfate | 17 | $257 |
| Doxycycline Hyclate | 15 | $212 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Teaneck
- Luis Gonzalez GonzalezTeaneck$58K
- Steven GreensteinTeaneck$23K
- Tamara LenisTeaneck$12K
- Ronald GlassmanTeaneck$9K
- Jai ParekhWoodland Park$2M
- Sharad MansukaniMoorestown$744K
- Ravi PatelEatontown$729K
- Cynthia MatossianPennington$655K
- Eric MannDover$604K
- Brett BieloryRutherford$477K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.